

National Adult Immunisation Schedule (NAIS)
(for persons age 18 years or older)

Vaccine	18-26 years	27-59 years	60-64 years	≥ 65 years
Influenza (INF)	1 dose annually or per season			1 dose annually or per season
Pneumococcal: • PCV20; <u>or</u> • PCV13 and/or PPSV23	1 dose of PCV20; <u>or</u> 1 dose of PCV13 and/or 1 or more doses of PPSV23, depending on age or medical condition(s)			
Shingles: Recombinant herpes zoster vaccine (RHZV)	2 doses			
Tetanus, reduced diphtheria and acellular pertussis (Tdap)	1 dose during each pregnancy			
Human papillomavirus (HPV2)	3 doses (Females)			
Hepatitis B (HepB)	3 doses			
Measles, mumps and rubella (MMR)	2 doses			
Varicella (VAR)	2 doses			

	Recommended for persons who meet age requirements
	Recommended for persons with specific medical condition or indication
	Recommended for persons who have not been previously vaccinated, or lack evidence of past infection or immunity

Recommended Vaccine Types, Doses and Groups in the NAIS – Influenza Vaccine		
Vaccine	Recommendations	Additional information
Influenza (INF)	<ul style="list-style-type: none"> Seasonal influenza vaccine is recommended for persons age 18 years or older who are at increased risk of influenza-related complications. Vaccination is recommended annually or per season, depending on the prevailing recommendations for vaccination that year. The use of SKYCellflu has not been evaluated in pregnant women 	<p>High-risk groups recommended for seasonal influenza vaccination</p> <p>- Persons age 65 years or older</p> <ul style="list-style-type: none"> Recommended for all persons <p>- Persons age 18 years or older with any of the following conditions:</p> <ul style="list-style-type: none"> who have chronic disorders of the pulmonary or cardiovascular systems, including asthma who have required medical follow-up or hospitalisation due to chronic metabolic diseases (including diabetes mellitus), renal, neurologic, hepatic, or haematologic disorders, or immunosuppression (including immunosuppression caused by medications, HIV or other immunodeficiencies) <p>- Other recommended groups</p> <ul style="list-style-type: none"> Persons age 18 years who are receiving long term aspirin therapy and therefore might be at risk for developing Reye syndrome after influenza infection Women at all stages of pregnancy Persons receiving intermediate and long-term care (ILTC) services

Recommended Vaccine Types, Doses and Groups in the NAIS – Pneumococcal Vaccines		
Vaccine	Recommendations	Additional information
Pneumococcal vaccine (summary)	<ul style="list-style-type: none"> For persons who are recommended for pneumococcal vaccination who have: <ul style="list-style-type: none"> - not previously received any pneumococcal vaccine can either receive: <ul style="list-style-type: none"> ○ PCV20; or ○ PCV13 and/or PPSV23 as per prevailing recommendations. - received PCV13 and/or PPSV23 but not completed the recommended vaccination series can either: <ul style="list-style-type: none"> ○ receive PCV20 to complete the vaccination series; or ○ complete the vaccination series as per prevailing recommendations using PCV13 and/or PPSV23. 	<ul style="list-style-type: none"> Refer to subsequent rows for recommendations specific to PCV20, PCV13 and PPSV23 Refer to separate guidance: DETAILED RECOMMENDATIONS ON PNEUMOCOCCAL VACCINES for scenarios by age, medical conditions or prior vaccine(s)
20-valent Pneumococcal conjugate vaccine (PCV20)	<ul style="list-style-type: none"> PCV20 is recommended for persons aged 18 years or older who are at increased risk of developing severe pneumococcal disease <p>Recommended dose</p> <ul style="list-style-type: none"> Only one dose of PCV20 is recommended regardless of age or conditions as listed in the high-risk groups 	<p>High-risk groups recommended for PCV20</p> <ul style="list-style-type: none"> Persons age 65 years or older Recommended for all persons Persons age 18 years or older with any of the following conditions: <ul style="list-style-type: none"> Chronic medical conditions, comprising: <ul style="list-style-type: none"> ○ Chronic pulmonary disease ○ Chronic cardiovascular disease ○ Chronic liver disease ○ Diabetes mellitus Cochlear implants or cerebrospinal fluid leaks; Immunocompromising conditions; Chronic kidney disease.
13-valent Pneumococcal conjugate vaccine (PCV13)	<ul style="list-style-type: none"> PCV13 is recommended for persons age 18 years or older who are at increased risk of developing severe pneumococcal disease <p>Recommended dose and interval</p> <ul style="list-style-type: none"> Only one dose of PCV13 is recommended regardless of age or conditions as listed in the high-risk groups If both PCV13 and PPSV23 are indicated, PCV13 should be given first, and PPSV23 administered at the appropriate interval later 	<p>High-risk groups recommended for PCV13</p> <ul style="list-style-type: none"> Persons age 65 years or older Recommended for all persons Persons age 18 years or older with any of the following conditions: <ul style="list-style-type: none"> Cochlear implant or cerebrospinal fluid leaks; Immunocompromising conditions; Chronic kidney disease.

Recommended Vaccine Types, Doses and Groups in the NAIS – Pneumococcal Vaccines		
Vaccine	Recommendations	Additional information
	<ul style="list-style-type: none"> If PCV20 is preferred to complete the vaccination series, refer to the separate guidance on the appropriate interval from prior dose of PCV13 (see DETAILED RECOMMENDATIONS ON PNEUMOCOCCAL VACCINES) 	
Pneumococcal polysaccharide (PPSV23)	<ul style="list-style-type: none"> PPSV23 is recommended for persons age 18 years or older who are at increased risk of developing severe pneumococcal disease <p>Recommended doses and interval</p> <ul style="list-style-type: none"> One or two doses of PPSV23 are recommended depending on age or conditions as listed in the high-risk groups If both PCV13 and PPSV23 are indicated, PCV13 should be given first, and PPSV23 administered at the appropriate interval later If PCV20 is preferred to complete the vaccination series, refer to the separate guidance on the appropriate interval from prior dose of PPSV23 (see DETAILED RECOMMENDATIONS ON PNEUMOCOCCAL VACCINES) 	<p>High-risk groups recommended for PPSV23</p> <p>- Persons age 65 years or older</p> <ul style="list-style-type: none"> Recommended for all persons <p>- Persons age 18 years or older with any of the following conditions:</p> <ul style="list-style-type: none"> Chronic medical conditions, comprising: <ul style="list-style-type: none"> Chronic pulmonary disease Chronic cardiovascular disease Chronic liver disease Diabetes mellitus Cochlear implants or cerebrospinal fluid leaks; Immunocompromising conditions; Chronic kidney disease.

Recommended Vaccine Types, Doses and Groups in the NAIS – RHZV		
Vaccine	Recommendations	Additional information
Recombinant herpes zoster vaccine (RHZV)	<ul style="list-style-type: none"> RHZV is recommended for persons aged 18 years or older who are at increased risk of developing shingles and associated complications <p>Recommended doses and interval</p> <ul style="list-style-type: none"> Persons age 60 years or older <ul style="list-style-type: none"> Two doses are recommended at an interval of 2-6 months Persons age 18 years or older with immunocompromising conditions <ul style="list-style-type: none"> Two doses are recommended. The interval can be shorter at 1-2 months if earlier protection is desired 	<p>High-risk groups recommended for RHZV</p> <ul style="list-style-type: none"> Persons age 60 years or older <ul style="list-style-type: none"> Recommended for all persons Persons age 18 years or older with any of the following immunocompromising conditions <ul style="list-style-type: none"> Primary or acquired immunodeficiency Iatrogenic immunosuppression <p>Refer to separate guidance: DETAILED RECOMMENDATIONS ON RHZV for examples of immunocompromised conditions</p> <p><u>Other recommendations</u></p> <p>Persons who have previously received live, attenuated herpes zoster vaccine (HZVL)</p> <ul style="list-style-type: none"> An interval of ≥5 years between HZVL and RHZV is recommended in general Due to lower efficacy of HZVL in adults aged 70 years or older, a shorter interval of ≥12 months between HZVL and RHZV can be considered A minimum interval of 8 weeks between HZVL and RHZV should be observed for all recommended age groups <p>Persons without a history of previous varicella infection, serological evidence of immunity or varicella vaccination</p> <ul style="list-style-type: none"> Verification of varicella immunity prior to receiving RHZV is not recommended regardless of age or medical condition

Recommended Vaccine Types, Doses and Groups in the NAIS – Tdap, HPV, HepB, MMR, Varicella		
Vaccine	Recommendations	Additional information
Tdap	<ul style="list-style-type: none"> Tdap is recommended during 16-32 weeks of each pregnancy for protection of infant against pertussis, regardless of the interval since the previous Td or Tdap vaccination. Tdap is recommended with each pregnancy to provide maximal protection to every infant, including pregnancies which are closely spaced (e.g. <2 years). 	<ul style="list-style-type: none"> Tdap can also be considered for pregnant women after 32nd week of gestation during each pregnancy. Maternal vaccination may afford less protection for infants, but would potentially protect the mother from pertussis infection and thereby reduce the risk of exposure to her infant. Both Adacel and Boostrix can be used in pregnant women.
HPV	<p>Recommended vaccine type</p> <ul style="list-style-type: none"> HPV2 (Cervarix) <p>Recommended doses for females age 18-26 years</p> <ul style="list-style-type: none"> 3-dose series at 0, 1, 6 months Minimum intervals between doses <ul style="list-style-type: none"> Dose 2: at least 4 weeks from dose 1 Dose 3: at least 20 weeks from dose 1 and 12 weeks from dose 2 	<ul style="list-style-type: none"> If HPV vaccination is initiated but not completed by age 26 years or earlier, remaining dose(s) may be completed after age 26 years, as early as possible, but up to age 45 years.
HepB	<ul style="list-style-type: none"> HepB is recommended for persons without evidence of immunity or prior disease. 3-doses series at 0, 1, 6 months 	-
MMR	<ul style="list-style-type: none"> MMR is recommended for persons without evidence of immunity or prior disease 2-dose series at least 4 weeks apart 	-
Varicella (VAR)	<ul style="list-style-type: none"> VAR is recommended for persons without evidence of immunity or prior disease 2-dose series 4-8 weeks apart 	-

National Adult Immunisation Schedule (NAIS):

Detailed recommendations on recombinant herpes zoster vaccine (RHZV)

Examples of immunocompromised conditions for recommendations on RHZV in the NAIS*	
Primary or acquired immunodeficiency	<ul style="list-style-type: none"> • Acute and chronic leukaemias • Chronic lymphoproliferative disorders including haematological malignancies, such as indolent lymphoma, chronic lymphoid leukaemia, myeloma, Waldenstrom's macroglobulinemia and other plasma cell dyscrasias • HIV infection (CD4 count <200 cells/μl), in an advanced state or untreated • Allogenic/autologous stem cell transplant in the previous 24 months • Stem cell transplant more than 24 months ago but have ongoing immunosuppression or graft versus host disease (GVHD) • Primary or acquired cellular and combined immune deficiencies
Iatrogenic immunosuppression	<ul style="list-style-type: none"> • Receiving or have received in the previous 6 months immunosuppressive therapy or medications for any indication • Examples of indication include cancer, solid organ transplant, chronic immune mediated inflammatory disease • Examples of therapy or medications include chemotherapy, radiotherapy, chronic use of corticosteroids, immunosuppressants for solid organ transplant, biologics, non-biologics • Does <u>not</u> include patients who had received a short course (<2 weeks) of high dose steroids for any reason • Targeted therapy for autoimmune disease (e.g. JAK inhibitors or biologic immune modulators)

* The examples of high-risk conditions, therapy and medications listed are non-exhaustive

Updated 21 August 2025

National Adult Immunisation Schedule (NAIS): Detailed recommendations on pneumococcal vaccines (PCV20, PCV13, PPSV23)

Scenarios by age, medical conditions, previous vaccine(s) received:

1. All persons aged ≥ 65 years
2. Persons in the recommended groups aged 18-64 years with chronic medical conditions
3. Persons in the recommended groups aged 18-64 years with cerebrospinal fluid leaks or cochlear implant
4. Persons in recommended groups aged 18-64 years with immunocompromising conditions or chronic kidney disease

Updated 21 August 2025

Detailed NAIS recommendations on pneumococcal vaccines:

1. All persons aged 65 years or older

Prior vaccines	<u>Option A:</u> PCV20 recommendations	<u>Option B:</u> PCV13 and/or PPSV23 recommendations
None	PCV20	PCV13; followed by PPSV23 (interval: ≥ 1 year*)
Received PPSV23 only (at any age)	PCV20 (interval: ≥ 1 year from PPSV23)	<<If previous PPSV23 was ≥ 65 years>> PCV13 (interval: ≥ 1 year from PPSV23)
		<<If previous PPSV23 was <65 years>> PCV13 (interval: ≥ 1 year from PPSV23); followed by PPSV23 (interval: ≥ 1 year)
Received PCV13 only (at any age)	PCV20 (interval: ≥ 1 year from PCV13)	PPSV23 (interval: ≥ 1 year from PCV13*)
Received PCV13 (any time) and PPSV23 (at <65 years)	PCV20 (interval: ≥ 5 years [†])	PPSV23 (intervals: see footnote [§])
Received PCV13 (any time) and PPSV23 (at ≥ 65 years) or Received PCV20 (any time)	No vaccines recommended Have already completed vaccination series	No vaccines recommended Have already completed vaccination series

* For persons with an immunocompromising condition, cochlear implant or CSF leak, a minimum interval of 8 weeks can be considered

† Interval of at least 5 years from any of the most recent dose of PCV13 or PPSV23

§ Intervals of at least 5 years from PPSV23 and at least 1 year from PCV13, whichever is later

Detailed NAIS recommendations on pneumococcal vaccines:

2. Persons in the recommended groups aged 18-64 years with chronic medical conditions

Prior vaccines	Option A: PCV20 recommendations	Option B: PPSV23 recommendations
None	PCV20	PPSV23
Received PPSV23 only	PCV20 (interval: ≥ 1 year from PPSV23)	No vaccines recommended at this time [†]
Received PCV13 only*	PCV20 (interval: ≥ 1 year from PCV13)	PPSV23 (interval: ≥ 1 year from PCV13)
Received PCV13 and 1 dose of PPSV23*	No vaccines recommended at this time [§]	No vaccines recommended at this time [§]

* Under the PCV13/PPSV23 recommendations, PCV13 is not recommended for persons with chronic medical conditions at this age

† If not opting for option A, review vaccine recommendations again when patient turns age 65 years, develops an immunocompromising condition or CSF leak, or requires a cochlear implant

§ Review vaccine recommendations again when patient turns age 65 years or develops an immunocompromising condition

Chronic medical conditions [¶]			
Chronic pulmonary disease	<ul style="list-style-type: none"> Chronic obstructive pulmonary disease (COPD) Chronic bronchitis and emphysema Conditions such as bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis and bronchopulmonary dysplasia (BPD) 	Chronic cardiovascular disease	<ul style="list-style-type: none"> Those requiring regular medication and/or follow-up for ischaemic heart disease, congenital heart disease, hypertension with cardiac complications, and chronic heart failure Does <u>not</u> include hypertension
Chronic liver disease	<ul style="list-style-type: none"> Biliary atresia; cirrhosis; chronic hepatitis Does <u>not</u> include hepatitis B carriers without liver inflammation/dysfunction or liver cirrhosis 	Diabetes mellitus	<ul style="list-style-type: none"> Does <u>not</u> include lipid disorders (e.g. hyperlipidaemia) Does <u>not</u> include pre-diabetes (e.g. impaired glucose tolerance, impaired fasting glucose)

¶ The examples of high-risk conditions listed are non-exhaustive within the respective condition or disease, unless otherwise indicated.

Detailed NAIS recommendations on pneumococcal vaccines:

3. Persons in the recommended groups aged 18-64 years with cerebrospinal fluid leaks or cochlear implant

Prior vaccines	<u>Option A:</u> PCV20 recommendations	<u>Option B:</u> PCV13 and/or PPSV23 recommendations
None	PCV20	PCV13; followed by PPSV23 (interval: ≥8 weeks)
Received PPSV23 only	PCV20 (interval: ≥1 year from PPSV23)	PCV13 (interval: ≥1 year from PPSV23)
Received PCV13 only	PCV20 (interval: ≥1 year from PCV13)	PPSV23 (interval: ≥8 weeks from PCV13)
Received PCV13 and 1 dose of PPSV23	PCV20 (interval: ≥5 years*)	No vaccines recommended at this time†

* Interval of at least 5 years from any of the most recent dose of PCV13 or PPSV23

† If not opting for option A, review vaccine recommendations again when patient turns age 65 years or develops an immunocompromising condition

Detailed NAIS recommendations on pneumococcal vaccines:

4. Persons in recommended groups aged 18-64 years with immunocompromising conditions or chronic kidney disease

Prior vaccines	<u>Option A:</u> PCV20 recommendations	<u>Option B:</u> PCV13 and/or PPSV23 recommendations
None	PCV20	PCV13; followed by PPSV23 (interval: ≥8 weeks); then followed by PPSV23 (interval: ≥5 years)
Received PPSV23 only	PCV20 (interval: ≥1 year from PPSV23)	<<Previously received 1 dose of PPSV23>> PCV13 (interval: ≥1 year from PPSV23); followed by PPSV23 (interval: see footnote†)
		<<Previously received 2 doses of PPSV23>> PCV13 (interval: ≥1 year from last dose of PPSV23)
Received PCV13 only	PCV20 (interval: ≥1 year)	PPSV23 (interval: ≥8 weeks from PCV13); followed by PPSV23 (interval: ≥5 years)
Received PCV13 and 1 dose of PPSV23	PCV20 [¶] (interval: ≥5 years*)	PPSV23 (interval: see footnote [§])
Received PCV13 and 2 doses of PPSV23	PCV20 [¶] (interval: ≥5 years*)	No vaccines recommended at this time [¶]

* Interval of at least 5 years from any of the most recent dose of PCV13 or PPSV23

† Intervals of at least 8 weeks from PCV13 **and** at least 5 years from the previous dose of PPSV23, **whichever is later**

§ Interval of at least 5 years from PPSV23 and at least 1 year from PCV13, **whichever is later**

¶ If not opting for option A, review vaccine recommendations again when patient turns age 65 years

Immunocompromising conditions**	<ul style="list-style-type: none"> • Congenital or acquired asplenia (including conditions that may lead to splenic dysfunction such as homozygous sickle cell disease and coeliac syndrome) • Congenital or acquired immunodeficiencies 	<ul style="list-style-type: none"> • HIV infection • Leukaemia • Lymphoma • Hodgkin's disease 	<ul style="list-style-type: none"> • Generalised malignancy • Iatrogenic immunosuppression • Solid organ transplant including renal transplant • Multiple myeloma
Chronic kidney disease***	<ul style="list-style-type: none"> • Nephrotic syndrome • Those on renal dialysis 	<ul style="list-style-type: none"> • Chronic kidney disease at stage 4 and 5 (excluding stage 1, 2 and 3) 	

** The examples of high-risk conditions are non-exhaustive within the respective condition or disease, unless otherwise indicated.

*** Coded as "renal insufficiency" in IT systems (e.g. Smart CMS, other CMS, MHCP)